Abstract
Thirty evaluable patients with advanced carcinoma of the pancreas received treatment with either daily x 5 bolus or continuous infusion x 5 days recombinant γ-interferon. No responses were noted. Major toxicities included fever, hypotension, and flu-like symptoms. γ-Interferon does not appear to be an active single agent for patients with advanced pancreatic cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 584-587 |
| Number of pages | 4 |
| Journal | Journal of Biological Response Modifiers |
| Volume | 9 |
| Issue number | 6 |
| State | Published - Dec 1990 |
Keywords
- γ-Interferon
- Pancreatic cancer
ASJC Scopus subject areas
- Cancer Research
- Immunology
- Pharmacology
Fingerprint Dive into the research topics of 'Phase II evaluation of recombinant γ-interferon in patients with advanced pancreatic carcinoma: A southwest oncology group study'. Together they form a unique fingerprint.
Cite this
von Hoff, D. D., Fleming, T. R., Macdonald, J. S., Goodman, P. J., Damme, J. V., Brown, T. D., O'Rourke, T., Feun, L. G., & Keppen, M. D. (1990). Phase II evaluation of recombinant γ-interferon in patients with advanced pancreatic carcinoma: A southwest oncology group study. Journal of Biological Response Modifiers, 9(6), 584-587.